Global Uterine Fibroid Treatment Market Set for 9.4% CAGR Through 2032

According to the latest market research study published by P&S Intelligence, the global uterine fibroid treatment market is witnessing rapid expansion, valued at USD 3.9 billion in 2024 and projected to nearly double to USD 7.9 billion by 2032, advancing at a robust CAGR of 9.4% (2025–2032). This strong growth is fueled by the increasing prevalence of uterine fibroids among women of reproductive age, a growing female geriatric population, and the rising incidence of hormonal conditions worldwide.

The market is undergoing a transformation with cutting-edge minimally invasive procedures, including uterine artery embolization (UAE), laparoscopic myomectomy, and high-intensity focused ultrasound (HIFU). These fertility-preserving and less invasive techniques are gaining significant adoption due to reduced recovery times, improved patient outcomes, and greater accessibility across hospitals and specialized centers. Furthermore, advances in MRI-guided focused ultrasound and radiofrequency ablation are reshaping clinical practices by offering safer and more precise treatment alternatives.

North America currently leads the market with its advanced healthcare infrastructure, rising patient awareness, and widespread adoption of modern diagnostic tools. Meanwhile, Asia-Pacific is set to experience the fastest growth, driven by increasing healthcare spending, medical tourism, and the adoption of minimally invasive treatments in countries such as China and India.

Leading players including Medtronic plc, Boston Scientific Corporation, AbbVie Inc., Pfizer Inc., Hologic Inc., and Bayer AG are actively investing in innovative treatment solutions. Recent approvals, such as Pfizer’s MYFEMBREE in Canada, and strong funding initiatives for advanced devices, are further accelerating market momentum.

Growing awareness campaigns such as the Fibroids Project and Fibroids Awareness Month are empowering women to seek early diagnosis and treatment, thereby fueling demand across all segments. With continuous advancements in pharmaceutical therapies, robotic-assisted surgeries, and AI-integrated imaging devices, the uterine fibroid treatment market is poised for unprecedented growth.

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

Contact: Abhishek AVP – Business Development Email: enquiry@psmarketresearch.com Web: https://www.psmarketresearch.com